GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin — A Complete Research Guide (2026)

# GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin — A Complete Research Guide (2026)

Growth hormone-releasing peptides (GHRPs) represent one of the most extensively studied classes of synthetic secretagogues in peptide research. As ghrelin-mimetic compounds that activate the growth hormone secretagogue receptor (GHS-R1a), GHRPs have been central to investigations of the somatotropic axis, metabolic regulation, and — in the case of hexarelin — cardiovascular biology. Yet despite their shared receptor target, each member of this family exhibits a distinct pharmacological fingerprint.

This guide compares the four primary GHRPs — GHRP-2, GHRP-6, ipamorelin, and hexarelin — across the dimensions that matter most in experimental design: receptor selectivity, GH release potency, off-target hormonal effects, unique biological applications, and practical research considerations. Researchers already familiar with individual peptide profiles can use this comparison to inform model selection; those new to GHRP biology will find context for understanding where each compound fits within the broader secretagogue landscape.

> Research Use Only (RUO) Disclaimer: All information in this article is provided for educational and research purposes only. These compounds are not approved for human or veterinary use. Any research involving these peptides must comply with applicable institutional and regulatory guidelines.

---

The GHS-R1a Receptor: A Common Target, Divergent Profiles

All four GHRPs share a common primary mechanism: agonism at the growth hormone secretagogue receptor 1a (GHS-R1a), a G protein-coupled receptor expressed on somatotrophs in the anterior pituitary and on neurons in the hypothalamic arcuate nucleus. The endogenous ligand for this receptor is ghrelin — a 28-amino acid acylated peptide produced primarily by gastric X/A cells.

When a GHRP binds GHS-R1a, it initiates intracellular signaling cascades that include phospholipase C activation, phosphatidylinositol (PI) turnover, protein kinase C (PKC) activation, and intracellular calcium mobilization. This leads to GH exocytosis from somatotrophs. However, GHS-R1a is not expressed exclusively in the pituitary — its presence in the hypothalamus, cardiovascular tissue, and other peripheral organs explains why GHRPs produce effects well beyond GH secretion.

An important mechanistic nuance: GHRP-mediated GH release is amplified by endogenous GHRH. Research in rats demonstrated that GHRP-6 requires functional hypothalamic GHRH signaling for maximal GH stimulation — passive immunization against GHRH substantially reduced the GH response (Pandya et al., 1998; PubMed 9543138). This synergistic relationship between GHRPs and GHRH analogs is foundational to understanding combination secretagogue research models.

---

Individual Compound Profiles at a Glance

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂)

GHRP-6 was among the earliest synthetic hexapeptide GHRPs characterized, and it remains the reference compound against which newer molecules are often benchmarked. It is a potent GHS-R1a agonist that stimulates robust GH release through both direct pituitary action and hypothalamic GHRH co-stimulation. Intracellular studies confirm that GHRP-6 drives dose-dependent PI turnover in human somatotroph cells, consistent with a Gq/11-mediated signaling mechanism (Lam et al., 1996; PubMed 7772238).

A distinguishing feature of GHRP-6 is its appetite-stimulating effect, mirroring ghrelin's orexigenic properties — an effect mediated in part through NPY/AgRP pathways in the hypothalamic arcuate nucleus. This makes GHRP-6 particularly relevant to appetite and energy homeostasis research models. Like GHRP-2, GHRP-6 administration produces significant elevations in plasma ACTH and cortisol, representing an off-target effect that must be accounted for in experimental design.

For the full GHRP-6 research profile, see our dedicated GHRP-6 Research Guide.

---

GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂ / Pralmorelin)

GHRP-2, also known by its INN designation pralmorelin, is a second-generation synthetic hexapeptide GHRP with notably high potency at GHS-R1a — though its Emax for GH release in some models is lower than GHRP-6 or ipamorelin (ED50 ≈ 0.6 nmol/kg in anesthetized rats, Emax ≈ 56 ng/mL). This apparently paradoxical combination of high affinity with moderate Emax reflects differences in receptor coupling efficiency and downstream amplification.

Where GHRP-2 distinguishes itself is in its established utility as a clinical diagnostic tool for GH deficiency and HPA axis assessment. A 2022 study demonstrated that the GHRP-2 stimulation test (GH-releasing peptide-2 test) is clinically useful for evaluating hypothalamic-pituitary disorders, with ACTH response cutoffs providing high specificity (100%) for pituitary-adrenal insufficiency (Tanaka et al., 2022; PubMed 35795807). Earlier research confirmed that GHRP-2-induced ACTH release is mediated primarily by hypothalamic corticotropin-releasing factor (CRF) (PubMed 15645295).

Like GHRP-6, GHRP-2 stimulates significant ACTH and cortisol elevation — a key similarity confirmed in direct human comparisons (Arvat et al., 1997; PubMed 9285939). See the full GHRP-2 (Pralmorelin) Research Profile for mechanism details and structural analysis.

---

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH₂)

Ipamorelin is a pentapeptide GHRP developed specifically to isolate GH-releasing activity while minimizing off-target endocrine stimulation. The landmark 1998 characterization study established ipamorelin as "the first selective growth hormone secretagogue" — demonstrating that at doses more than 200-fold above the ED50 for GH release, ipamorelin did not produce statistically significant elevations in ACTH or cortisol compared to GHRH controls (Raun et al., 1998; PubMed 9849822).

This selectivity profile is ipamorelin's defining research advantage. In experimental contexts where HPA axis confounding is a concern — stress response studies, metabolic models, longitudinal hormone assays — ipamorelin's clean GH selectivity simplifies interpretation. Its GH release potency (ED50 ≈ 80 nmol/kg, Emax ≈ 1,545 ng/mL in anesthetized rats) is comparable to GHRP-6 but substantially higher in Emax — a particularly notable contrast given ipamorelin's superior selectivity.

Research applications extend beyond GH secretagogue studies: ipamorelin has been investigated in nitrogen balance models in steroid-treated experimental subjects, GI motility research (GHS-R1a is expressed in the enteric nervous system), and as a component of combination secretagogue protocols alongside GHRH analogs such as CJC-1295.

For the full mechanistic breakdown, see the Ipamorelin Research Profile.

---

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂)

Hexarelin is a synthetic hexapeptide with the highest reported GH-releasing potency among the four primary GHRPs in multiple comparative models. Its structural analog to GHRP-6 — incorporating a 2-methyltryptophan residue — confers enhanced GHS-R1a binding affinity and correspondingly robust GH responses. Like GHRP-2 and GHRP-6, hexarelin produces significant ACTH and cortisol stimulation, with age-related attenuation of the GH but not ACTH/cortisol response documented across life stages (PubMed 9437229).

What truly differentiates hexarelin in the research landscape is its extensive cardiology application — an effect that is independent of its GH-secreting activity. Hexarelin binds not only GHS-R1a but also CD36, a scavenger receptor expressed on cardiomyocytes and macrophages. Through these dual receptor interactions, hexarelin has demonstrated cardioprotective effects in multiple experimental cardiac models:

• •Protection against ischemia/reperfusion injury through modification of the IL-1 signaling pathway (PubMed 28321024)
• •Improved cardiac function following experimental myocardial infarction in rats (PubMed 10614623)
• •Protection of isolated rat heart from ventricular dysfunction induced by calcium-free medium exposure (PubMed 10887041)
• •Improved cardiac performance in human patients with coronary artery disease during bypass surgery, via a GH-independent mechanism (PubMed 12144941)

This cardiotropic profile makes hexarelin uniquely relevant to cardiovascular biology research in ways that GHRP-2, GHRP-6, and ipamorelin do not replicate.

Read the complete Hexarelin Research Profile for a full mechanistic analysis.

---

Head-to-Head Comparison Table

---

Selectivity: The Defining Differentiator

The most critical dimension separating these four GHRPs is endocrine selectivity — specifically, the degree to which each compound activates the HPA axis alongside GHS-R1a.

GHRP-6, GHRP-2, and hexarelin all produce statistically significant and dose-dependent elevations in plasma ACTH and cortisol in research models. In the foundational human comparison study, both GHRP-2 and hexarelin produced ACTH and cortisol responses that were similar to each other, and significantly higher than GHRH controls (Arvat et al., 1997; PubMed 9285939). For studies examining the somatotropic axis in isolation, this HPA co-activation represents a significant confound — cortisol itself has complex modulatory effects on GH secretion and downstream IGF-1 production.

Ipamorelin is the exception. The selectivity data from Raun et al. (1998) remains compelling: at doses 200× above the GH ED50, ipamorelin failed to produce ACTH or cortisol levels meaningfully different from GHRH stimulation — a benchmark that neither GHRP-6 nor GHRP-2 can match (PubMed 9849822). For research designs requiring clean GH axis interrogation, ipamorelin remains the gold-standard GHRP.

---

GH Release Potency and Temporal Dynamics

Comparing GH release potency across these peptides requires careful attention to model system, dose, and assay conditions. In anesthetized rat models:

• •Hexarelin demonstrates the highest observed peak GH responses in several comparative protocols, consistent with its higher GHS-R1a binding affinity
• •Ipamorelin achieves high Emax values (≈1,545 ng/mL) with an ED50 of approximately 80 nmol/kg, comparable to GHRP-6
• •GHRP-6 shows similar Emax (~1,167 ng/mL) with ED50 ≈ 115 nmol/kg
• •GHRP-2 demonstrates high potency (ED50 ≈ 0.6 nmol/kg) but paradoxically lower Emax (~56 ng/mL) — suggesting partial agonism characteristics or differential receptor coupling in certain systems

GH pulse duration also varies between compounds. Hexarelin and ipamorelin produce discrete, physiologically-timed GH pulses that more closely mimic endogenous GH secretory patterns when combined with GHRH analogs. The synergistic interaction between any GHRP and a GHRH analog (sermorelin, CJC-1295, or tesamorelin) results in substantially greater GH release than either compound alone — a principle documented consistently across experimental models.

---

Unique Biological Applications

Hexarelin: Cardiovascular Biology

Hexarelin is the only GHRP with well-documented, GH-independent cardioprotective mechanisms. Its binding to CD36 on cardiomyocytes and macrophages positions hexarelin uniquely in cardiovascular research models examining ischemia/reperfusion injury, cardiac contractility, and mitochondrial calcium handling. Researchers investigating cardiac biology who require a GHRP should consider hexarelin specifically for these co-applications.

GHRP-2: HPA Axis and Diagnostic Research

GHRP-2's utility as a GH stimulation test agent — validated against insulin tolerance test and other provocation protocols — makes it the preferred GHRP for research models involving pituitary-hypothalamic function assessment. The GHRP-2 test's capacity to simultaneously probe GH reserve and adrenal function (via ACTH co-stimulation) has clinical diagnostic precedent in Japan, making GHRP-2 literature particularly relevant to translational endocrinology research.

Ipamorelin: Pure Somatotropic and GI Research

When the research goal is to probe GH signaling without HPA axis confounding, ipamorelin is the logical selection. Its application extends to GI motility research (enteric GHS-R1a expression), nitrogen metabolism studies, and any experimental context where the researcher needs GH effects without cortisol co-elevation. Ipamorelin is also frequently combined with GHRH analogs (notably CJC-1295) in pulse-mimicry protocols.

GHRP-6: Appetite, Ghrelin Biology, and Reference Compound

GHRP-6 remains the most ghrelin-like of the four GHRPs in terms of appetite-stimulating effects mediated through arcuate nucleus NPY/AgRP pathways. Research models examining appetite regulation, energy homeostasis, or the interface between GH secretion and metabolic signaling often use GHRP-6 as the primary compound because it most closely recapitulates ghrelin's pleiotropic biology.

---

Stability and Reconstitution Considerations

All four GHRPs share common storage and handling requirements relevant to research workflows:

• •Storage: Lyophilized powder is stable at -20°C for extended periods; avoid freeze-thaw cycles once reconstituted
• •Reconstitution: Bacteriostatic water or sterile water (0.9% acetic acid for improved solubility with certain peptides); see our Peptide Reconstitution Guide for protocol
• •Stability in solution: Reconstituted peptides are generally stable for 2-4 weeks at 4°C; longer storage should remain frozen
• •Degradation pathways: GHRPs are susceptible to proteolytic cleavage, particularly by serum dipeptidyl peptidase IV (DPP-IV) and other endopeptidases; this influences observed half-lives in in vitro and in vivo models

For a broader discussion of peptide stability, see Peptide Storage and Stability: Everything Researchers Need to Know.

---

Selecting the Right GHRP for Your Research Model

The choice among GHRP-2, GHRP-6, ipamorelin, and hexarelin should be driven by the specific research question rather than GH release magnitude alone. A framework for selection:

Use ipamorelin when:

• •GH axis selectivity is critical (minimal HPA axis confounding required)
• •Combining with a GHRH analog for pulse-mimicry protocols
• •Studying GI motility or enteric nervous system GHS-R1a biology
• •Long-term metabolic or nitrogen balance studies are planned

Use hexarelin when:

• •Cardiovascular research is a primary or secondary aim
• •Maximum GH release amplitude is required
• •Investigating CD36 receptor biology or mitochondrial calcium dynamics
• •Cardiac ischemia/reperfusion injury models are the focus

Use GHRP-2 when:

• •Diagnostic or translational endocrinology research models are the goal
• •HPA axis co-stimulation is an intended part of the experimental design
• •High GHS-R1a binding potency at low concentrations is needed
• •Alignment with Japanese clinical GHRP-2 test literature is relevant

Use GHRP-6 when:

• •Ghrelin biology and appetite regulation are research targets
• •A reference GHRP with the most extensive historical literature is needed
• •Appetite-stimulating effects are a feature (not a confound) of the model
• •GH effects alongside orexigenic biology are both under investigation

---

Relationship to Other Growth Hormone Axis Peptides

GHRPs do not operate in isolation within the broader growth hormone axis. Researchers working in this space should be aware of the mechanistic relationships with:

• •GHRH analogs (sermorelin, CJC-1295, tesamorelin): act on the GHRH receptor (GHRHR) — a distinct receptor from GHS-R1a — and synergize powerfully with all four GHRPs. See the GHRH Analogs Compared Guide for a parallel analysis of that compound class.
• •MK-677 (ibutamoren): an orally active, non-peptide GHS-R1a agonist with distinct pharmacokinetics. Relevant comparison for researchers evaluating secretagogue delivery routes. See MK-677 Research Profile.
• •IGF-1 and IGF-1 LR3: downstream effectors of GH signaling; GHRP-mediated GH secretion ultimately drives hepatic IGF-1 production, making IGF-1 a relevant downstream biomarker in most GHRP research models. See IGF-1 Research Profile and IGF-1 LR3 Research Profile.

---

Conclusion

GHRPs are not interchangeable despite their common receptor target. Ipamorelin's superior endocrine selectivity makes it the preferred compound for clean GH axis research. Hexarelin's dual GHS-R1a/CD36 engagement and well-documented cardiotropic effects distinguish it uniquely for cardiovascular biology. GHRP-2's diagnostic research pedigree and dual GH/HPA co-stimulation profile serve specialized endocrinology models. GHRP-6, as the most ghrelin-like member, remains the reference compound for appetite and metabolic research.

Selecting among these four GHRPs requires clarity about what the experiment is actually measuring — GH release kinetics, HPA axis responsiveness, cardiac function, or orexigenic biology. Used with that clarity, each compound offers distinct and well-characterized research value.

---

All content is for educational and research purposes only. These compounds are designated for in vitro and research use only, and are not approved for human or veterinary administration. Researchers should consult all applicable institutional and regulatory guidelines before handling these materials.

References:

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed 9849822

2. Pandya N, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Endocrinol. 1998;157(3):423-430. PubMed 9543138

3. Lam KS, et al. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. Clin Endocrinol (Oxf). 1996;44(2):151-156. PubMed 7772238

4. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. J Endocrinol Invest. 1997;20(7):447-451. PubMed 9285939

5. Tanaka T, et al. Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder. J Endocr Soc. 2022;6(8):bvac088. PubMed 35795807

6. Beiras-Fernandez A, et al. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury. Front Physiol. 2017;8:100. PubMed 28321024

7. Bisi G, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur J Pharmacol. 2002;448(2-3):193-200. PubMed 12144941

8. Tivesten A, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology. 2000;141(1):60-66. PubMed 10614623

9. Ghigo E, et al. The GH, prolactin, ACTH and cortisol responses to hexarelin undergo different age-related variations. Eur J Endocrinol. 1997;136(4):432-438. PubMed 9437229

---

Further Reading:

• •Ipamorelin vs GHRP-2: Growth Hormone Secretagogue Comparison for Researchers (2026)
• •Ipamorelin vs GHRP-6: Research Comparison Guide 2026
• •GHRP-2 (Pralmorelin): The Potent Second-Generation Growth Hormone Secretagogue — Complete Research Profile
• •CJC-1295 + Ipamorelin Stack Guide: Dosing, Cost Analysis, and Where to Buy (2026)
• •Reconstitution Calculator
• •Peptide Stack Builder